CYP2D6 Metabolizer Status and Mortality in Metoprolol Users
Simon de Denus, Essaïd Oussaïd, Maxime Meloche, Antoine‐Xavier Bertrand, Grégoire Leclair, Marie‐Christyne Cyr, Martin Jutras, Marie‐Josée Gaulin, Ian Mongrain, David Busseuil, Jean‐Claude Tardif, Marie‐Pierre Dubé · 2026
Read CYP2D6 Metabolizer Status and Mortality in Metoprolol Users by Simon de Denus, Essaïd Oussaïd, Maxime Meloche, Antoine‐Xavier Bertrand, Grégoire Leclair, Marie‐Christyne Cyr, Martin Jutras, Marie‐Josée Gaulin, Ian Mongrain, David Busseuil, Jean‐Claude Tardif, Marie‐Pierre Dubé (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13532063.txt.
Description
Simon de Denus and co-authors ask whether gene-based drug handling affects survival in users of a common heart drug, in work from 2026. The drug, metoprolol, is broken down by an enzyme whose speed varies by gene type. That speed changes drug levels and heart response in clear ways.
The study drew on a heart institute cohort in Montreal. Blood samples from 996 patients on the drug were tested for drug level and gene type. About a quarter of patients had died at follow-up, which ran a median of near eight and a half years. Models adjusted for age, sex, heart history, and other drugs. Early results link faster gene types to survival in a graded way.
Catalog record
| CREATOR | Simon de Denus, Essaïd Oussaïd, Maxime Meloche, Antoine‐Xavier Bertrand, Grégoire Leclair, Marie‐Christyne Cyr, Martin Jutras, Marie‐Josée Gaulin, Ian Mongrain, David Busseuil, Jean‐Claude Tardif, Marie‐Pierre Dubé |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |